Citius Oncology annual free cash flow
2024
2025
Citius Oncology Free Cash Flow (FCF) History (CTOR)
Citius Oncology reported −$11.2M in free cash flow for fiscal 2025, a decrease of $6.4M from the previous fiscal year.
View full Citius Oncology company overviewCitius Oncology free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-09-30 | −$11.2M | −$6.4M | — | — |
| 2024 | 2024-09-30 | −$4.9M | — | — | — |
Citius Oncology quarterly free cash flow
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | −$4.7M | — | — | −315.35% |
| Q2 2026 | 2026-03-31 | −$4.4M | — | — | −265.80% |
| Q1 2026 | 2025-12-31 | −$11.8M | — | — | −298.04% |
Citius Oncology free cash flow growth trends
Citius Oncology's latest reported quarter, Q3 2026, generated −$4.7M in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Citius Oncology source filings ↗Community posts
Citius Oncology’s wholesaler shipments rise sharply while institutional orders grow modestly
Citius Oncology ($CTOR) reported preliminary sales of 792 Lymphir units to US wholesalers for its fiscal fourth quarter of 2026, up 120% from 360 in the preceding quarter. Separately, prescribing centers ordered 950 vials from wholesalers, ...
